US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Invitation to Asarina Pharma R&D Day 2020

Asarina Pharma invites institutional investors, financial analysts and media to join its R&D day, focused on the upcoming Study results in the company's lead indication PMDD.Date: March 26, 2020 Time: 14.00-17.00, registration from 13.30 Location: Helio GT30, Grev Turegatan 30, Stockholm With presentations from PMDD practitioners and patients, as well as Asarina Pharma’s leading researchers and managers, the day will give a broad picture of PMDD, what the most meaningful clinical effects for a treatment are, and how the company's upcoming Phase IIb data will be evaluated and

Asarina Pharma: Redeye reports positively on new directed share issue

October 25, 2019: Redeye: “We see Asarina Pharma as one of the truly undiscovered biotech cases on the Scandinavian stock markets. We argue that the prospects for showing good results in its PMDD Phase IIb Study are good, which is not at all reflected in the stock price at present.”On October 24 Asarina Pharma (publ) (ASAP) announced a new, directed share issue worth approximately 48 MSEK. Subscribers include Handelsbanken, Sweden’s Fourth AP Fund, Swedbank Robur and Östersjöstiftelsen. Asarina Pharma CEO Peter Nordkild: “We're proud major long-term Swedish investors like Fourth AP Fund,

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe